Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Pain Management in Hidradenitis Suppurativa: Current Medical and Surgical Management
Description
The presentation focuses on pain management in patients with Hidradenitis Suppurativa (HS), highlighting the significant impact chronic pain has on quality of life—comparable to conditions requiring urgent medical intervention such as end-stage heart failure. Patients typically experience moderate to severe pain, which is often poorly managed due to hesitance from healthcare providers and lack of specific guidelines. Pain in HS is complex, potentially involving both nociceptive and neuropathic components, demanding a multifaceted approach to treatment. Current management primarily emphasizes controlling the underlying inflammatory disease while also addressing pain effectively. While opiates are to be limited, other treatments include acetaminophen and potential alternatives like gabapentin or pregabalin for chronic pain. The speaker advocates for better communication between patients and providers, encouraging discussions about pain to develop safer, individualized pain management strategies. New research is planned to explore pain trajectories within HS patients, ultimately aiming to enhance therapeutic approaches tailored to individual patient needs.
View moreConclusions
- Pain is the most significant symptom affecting quality of life in patients with hidradenitis suppurativa (HS).
- Most HS patients experience moderate to severe pain, significantly impacting their daily activities.
- A two-point increase in pain severity correlates with a quality of life reduction similar to disease progression from Hurley stage 1 to stage 3.
- HS pain is often managed in silence, with patients frequently self-managing their pain without professional assistance, leading to potentially dangerous practices.
- Pain in HS can result from multiple mechanisms including nociceptive, neuropathic, and nociplastic pain.
- Current treatments for HS do not adequately control pain, with minimal improvement observed in clinical trials for pain reduction.
- Guidelines recommend a multimodal approach for pain management, including disease control and appropriate pharmacologic therapies.
- Patients and healthcare providers often face barriers to effective pain management, including stigma and inadequate training.
- There is a critical need for effective pain treatment strategies and guidelines specifically tailored to HS patients.
- Nielson RM. BJD. 2019; doi: 10.1111/bjd.17935
- Li Y et al. Dermatol. 2023; 159:1102-1111. PMID: 377175623
- Curseen KA et al. Br J Dermatol. 2023; 188: 41-51. Advance access publication date: 7 November 2022
- Jedrzejczak MJ et al. JAMA Dermatol. 2021;157(4):464-466. doi:10.1001/jamadermatol.2020.5857
- Kimball AB et al. JAAD. 2018;79:1141-1143. PMID: 29787843
- Garcovich S. J Clin Med. 2020; 9(12): 4046. PMID: 33333779
- Huilaja L. JAAD. 2019. PMID: 31730843
- Aarts P. JAMA Derm. 2021; 157(10):1209-1212. PMID:34406352
- Tsentemeidou A. Dermatol Pract Concept. 2022; 12(2):e2022099. PMID: 35646432
- Orenstein LAV et al. Br J Dermatol. 2023;188(1):41-51. PMID:36689519
- Jørgensen AHR. Actas Dermosifiliogr. 2021;112(2):153-158. PMID: 33232705
- Li YH. Dermatological Reviews. 2022; 1-13. doi: 10.1002/der2.122
- Enamandram M. JAAD. 2015; 73(4): 563-573
- Webster L et al. Pain Medicine. 2020; 21:714. PMID: 31917418